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Abstract
Aim: Early intervention programmes
are expected to result in the reduction
of illness severity in patients with
schizophrenia, and contain health-
care costs by reducing hospital
admissions and improving the
social functioning of patients. This
study aimed to investigate the cost-
effectiveness of treatment in an early
intervention programme in compari-
son to standard care.
Methods: Retrospective analysis of
data prospectively recorded in an
urban area (Milan, Italy). Twenty-
three patients from an early interven-
tion programme and 23 patients from
standard care with first-episode psy-
chosis were evaluated on their use of
services over a 5-year period. The
Health of the Nation Outcome Scale
was used to measure clinical status.
Results: Significant changes with
respect to initial assessment were
recorded on the Health of the Nation
Outcome Scale, with larger effect sizes
in the early intervention programme
than in the standard care group. Con-
sequently, the cost-effectiveness ratio
per reduced score of severity was
lower in the early intervention pro-
gramme than in standard care (€ 4802
vs. € 9871), with an incremental cost-
effectiveness ratio, or net saving of
€ -1204 for every incremental reduced
score of severity. Over time, greater
recourse to hospital and residential
facilities to obtain comparable
improvement in symptoms resulted
in a steady cost increase for the
patients in standard care.
Conclusions: Allocation of funds to
specialized early intervention pro-
grammes is the best alternative, as it
can save costs by reducing the use of
hospitals and residential facilities,
and may produce net savings of costs
in the long term.
Key words: cost-effectiveness, early intervention, HoNOS, psychosis,
schizophrenia.
INTRODUCTION
Schizophrenia is a chronic and severe disorder,
which negatively impacts the lives of affected
patients and their families.1–3 Costs for patients,
their families and the society largely depend on
costs for care although additional costs arise from
lost productivity (because of unemployment and
work absences for both patients and the relatives
caring for them), informal care, involvement of
criminal justice services and costs related to social
security.4–6
Early detection and early interventions (EIs) in
patients with psychosis aim to limit the most dam-
aging outcomes of co-morbidity, namely, including
depression, substance abuse and vocational disrup-
tion, so as to reduce the risk of social drift of the
patient.7,8 These measures are expected to prevent
the development of a chronic course,9,10 and
maximize the chances of social and occupational
functioning.11,12
From a theoretical standpoint, early interven-
tion programmes (EIPs) are expected to decrease
illness severity of schizophrenia and hence contain
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healthcare costs by reducing the number of hospital
admissions and by improving patients’ social func-
tioning thus lessening the burden of informal care
by relatives. Some evidence exists on the effective-
ness of phase-specific early interventions for people
with psychosis,10,13,14 by increasing rates of remission
and decreasing admission rates and hospital
stays.15,16 However, precise evidence on the cost-
effectiveness of such programmes is limited.17 Two
studies found significantly better social functioning
and symptomatic outcome after the first year of
treatment in patients treated by EI services com-
pared with historical matched groups who received
treatment-as-usual, with lower costs in EIPs
because of lower inpatient costs.16,18
More recently, data from the Early Psychosis Pre-
vention and Intervention Centre (EPPIC), in Mel-
bourne, Australia, demonstrated significantly better
social and symptomatic outcomes among a cohort
8 years after initial 2-year EPPIC treatment com-
pared with a historical treatment-as-usual group,
with significantly lower costs for treatment per
annum in the EPPIC group.17
To date, no study has analysed data on patients
who underwent a full 5-year specialized protocol of
care in an EI service, with this period arguably being
the most critical as far as the long-term follow-up is
concerned.17,19
This paper summarizes data on the cost-
effectiveness of treatment as part of the Program-
mema2000, a comprehensive programme operating
in Italy since 1999,20 which provides focused inten-
sive treatment at the onset of psychosis, by compar-
ing patients treated with standard care (SC) – or
treatment-as-usual – in the same health district
(Milan). Prospectively collected data concerning a
5-year interval, from assessment at inception to the
final end point, were used in the study.
METHODS
The setting
Programma2000 was established in a health-care
catchment area of inner Milan (Italy), which pro-
vides services to approximately 200 000 inhabitants.
The focus area has a dedicated Community Mental
Health Center (CMHC) open 9 h a day, 5 days a
week, throughout the year.20
The main inclusion criteria are: first, contact with
any public mental health service of the catchment
area for a first episode of psychosis with a duration
of untreated psychosis (DUP) 24 months, for
people aged 17–30 years old.
All patients who are referred to Programma2000
receive a prompt admission in treatment (within
24 h), and undergo a comprehensive, multidimen-
sional evaluation with a package of standardized
assessments aimed at evaluating general psycho-
pathology, level of functioning and associated
impairment, disability and cognitive deficits.20,21
Proposed interventions include individual phar-
macotherapy, psychoeducational and motivational
sessions, cognitive–behavioural psychotherapy
(CBT), individual family psychoeducation and
therapeutic support group activities (e.g. anxiety
management, social problem-solving, assertive
training, substance abuse prevention, etc.), various
social group activities (e.g. musical group, multime-
dia group, computer training sessions, language
courses, empowerment group), and other support
activities (concerning employment, school, compli-
ance with medication, recreational planning).20
Hospital admissions, when necessary, are negoti-
ated with the twoGeneral Hospital Psychiatric Units
(GHPUs) operating in the same area. The beds avail-
able for hospital treatment were 11 per 100 000
when the study was conducted.
All interventions are free of charge for admitted
patients and are financed through a special grant
from the Lombardy Regional Authority. The length
of care under the programme is set at 5 years from
the time of initial assessment.
The comparison group included patients
treated in SC. By SC, we mean any specialized
mental health provision not offering interventions
specifically aimed at treating the first-episode of
psychosis.
To make the comparison with SC services, the
study included public outpatient and inpatient psy-
chiatric facilities operating in the same catchment
area (Milan and the surrounding health district),
which provide services to approximately 400 000
inhabitants. There were two GHPUs and four
CMHCs involved in the study.
All public psychiatric facilities are open 24 h a
day, with staff on duty at night; pharmacotherapy
and individual supportive psychotherapy are the
main treatment methods for patients with psycho-
sis.22,23 Co-morbidity for substance abuse is treated
in cooperation with a dedicated team, which is
external to the psychiatric service and works as
part of Drug Addiction Services.23 School support,
vocational (re)habilitation and competency train-
ing generally are not offered to patients with psy-
chosis in SC, and in the health district covering the
Lombardy Regional Authority complex care pack-
ages were rarely provided in SC.24 A specific proto-
col of care is not active for patients with psychosis
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at their first episode. Patients are seen within
7–15 days from the request for intervention: they
receive a clinical interview to ascertain diagnosis
and co-morbidity, and are prescribed pharmaco-
therapy and individual supportive psychotherapy.25
Contacts are one-two per month, unless a patient
requires more frequent visits. In this case, patients
are usually admitted to day-hospital or community
residential or semi-residential facilities. In these
settings, generic group therapy and social skills
training are provided as adjunctive treatment. For
patients with acute illness, admissions are negoti-
ated with the GHPUs operating in the same area.
The beds available for hospital treatment were 10
per 100 000 when the study was performed.
Families receive information on the illness and
psychological support when needed, but struc-
tured psychoeducation and family therapy are not
provided.25
Participants
All patients enrolled in Programma2000 who were
diagnosed with schizophrenia or related disorders
(International Classification of Diseases–10 codes:
F20 and F21–29)26 with DUP 24 months, and who
completed the 5-year treatment by the end of Sep-
tember 2008, were evaluated and included in the
study (n = 23).
The comparison group came from a parallel
study investigating severity and costs in patients
diagnosed with schizophrenia. This group includes
23 patients who received public psychiatric ser-
vices in the same health district but in different
units, were treated for a first episode of psychosis
and were diagnosed with schizophrenia or a
related disorder (in line with Programma2000). To
select this sample, we examined clinical records for
SC patients who complied with inclusion and
exclusion criteria, including age (17–30 years old)
and DUP (24 months) limits, and completed a
five-year treatment by the end of September 2007.
At the end of September 2008, 23 SC patients met
the criteria, resulting in a matched group in terms
of sample size.
In both groups, a co-morbid, persistent
substance-dependence disorder was an exclusion
criterion, however substance use/abuse without
dependence was not.
Patients in both groups were treated for 5 years,
and there were no dropouts.
The institutional review boards of the involved
services approved the study, and all patients gave
their informed consent.
Effectiveness measures
Patients enrolled in the Programma2000 undergo a
detailed assessment protocol20 that uses various
psychiatric scales, but patients enrolled in SC were
not assessed in detail. Both groups were assessed on
theHealth of theNationOutcome Scales (HoNOS),27
which is a widely used measure of outcome devel-
oped for routine use in mental health services. The
treating clinicians assigned the scores on the
HoNOS.
HoNOS consists of 12 subscales, each using the
5-point Likert scale (from 0, ‘no problem’, to 4,
‘severe/very severe’). Scores can be totalled to a
theoretical maximum of 48 points. Cut-offs used to
determine the clinical status of patients have been
proposed and validated in the Italian setting.28 For
the purpose of this study, as an effectiveness
measure, we used the average per patient total
score reduction between entry and 5-year
follow-up and the reliable change index (RC). RC
refers to the extent to which an observed change
falls beyond the range attributable to the measure-
ment error: RC was set at 7, in accordance with the
suggested threshold for severe patients.28 On the
basis of the percentage of patients achieving RC,
the number needed to treat (NNT) was calculated
as such: 100/(Percent Improved Programma2000 –
Percent Improved in SC). Suggested thresholds for
interpreting NNT are: small = 8.8; medium = 3.6;
large = 2.3.29
The interrater reliability asmeasured by the intra-
class correlation coefficient for the HoNOS at 5-year
follow-up was found to be 0.771 (95% confidence
interval (CI): 0.605–0.888) in the index group
(Programma2000), and 0.710 (95% CI: 0.498–0.858)
in the control (SC) group. Despite the larger CI in
the SC group, reliability estimates did not differ
(c2 = 0.274, degrees of freedom (d.f.) = 1, P = 0.60),
according to Hakstian andWhalen.30
Costs
Treatment costs were calculated by multiplying the
different items of services used by each patient
times their unit costs. Only direct health-care costs
falling on the Italian National Health Service were
analysed. These are grouped into three types of
treatment: CMHCs interventions (outpatient costs),
inpatient care (use of psychiatric acute beds and day
hospital admissions), and time spent living in com-
munity residential and semi-residential facilities
(residential costs). The records on items of services
used were made available by the Department of
Health of the Lombardy Region, while unit costs
C. Angelo et al.
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were derived from a previous study, based on 10
psychiatric service centres of the Lombardy
Region.31 All unit costs were expressed at 2006 con-
stant prices in Euros, €), in order to avoid influence
of yearly price increases. In the sensitivity analysis,
patient costs were discounted at 3% and 5% rates.
Data analyses
The index (Programma2000) and the contrast (Stan-
dard Care) groups were compared with respect to
clinical effectiveness (reduction of HoNOS scores
after 5 years; number of patients with RC) and costs
(total, outpatient interventions, hospital and resi-
dential facilities admissions). In addition, the profile
of costs was calculated across the 5 years of treat-
ment for each patient.
All data were coded and analysed using the Statis-
tical Package for Social Science for Windows (SPSS
Inc., Chicago, IL, USA), version 13. Categorical data
were analysed in inter-group comparisons with chi-
squared of Fisher’s exact test, when appropriate.
Student’s t-test was used to compare age. Analysis of
covariance was used to compare HoNOS scores at
the 5-year follow-up, taking HoNOS scores at the
initial assessment as covariate. The Mann–Whitney
test and theWilcoxon signed rank test were used to
compare ordinal variables and costs. The non-
parametric Friedman test for repeated measures
(with the Dunnmultiple comparison test for further
post hoc comparisons) was used to compare costs
over time. All tests were two-tailed, with a = 0.05.
For HoNOS, effect sizes of statistically significant
differences were expressed through Hedges’ g (a
bias corrected version of Cohen’s d) with 95%CI: for
intervention costs, the area under the receiver oper-
ating characteristic area (area under the curve, AUC)
was used; when 95% CIs are both above 0.500
(equiprobability), the effect size of the difference
can be considered statistically reliable.29
RESULTS
General characteristics of the sample
The two samples did not differ at entry by age, sex,
educational and/or occupational level, or diagnosis,
nor didHoNOS scores differ at assessment (Table 1).
The patients of Programma2000 were treated on
average for 4.8 years (1756 days), while those of the
control group for 5.1 year (1863 days).
Effectiveness
In both groups, after a 5-year period there were sig-
nificant changes on the HoNOS compared with
initial assessment (Wilcoxon signed rank test:
z = -3.408, P = 0.001 in Programma2000; z = -2.960,
P = 0.003 in SC). There were larger effect sizes in the
Programma2000 than in the SC group (Table 2).
TABLE 1. Socio–demographic and clinical characteristics of the sample
Programma2000
n = 23 (%)
Standard Care
n = 23
Statistics
Age (SD) 24.5 (3.9) 25.8 (3.6) t = -1.16, d.f. = 44, P = 0.25
Sex c2 = 0.00, d.f. = 1, P = 1.00
Male 16 (69.6) 17 (73.9)
Female 7 (30.4) 6 (26.1)
Educational qualification c2 = 0.82, d.f. = 1, P = 0.365
Lower than high school diploma 12 (52.2) 16 (69.6)
High school diploma or higher 11 (47.8) 7 (30.4)
Marital status c2 = 0.27, d.f. = 1, P = 0.60
Single 22 (95.7) 20 (87.0)
Married 1 (4.3) 3 (13.0)
Occupational status c2 = 1.493 d.f. = 1, P = 0.22
Student/housewife/unemployed 17 (73.9) 12 (52.2)
Part-time/fully Employed 6 (26.1) 11 (47.8)
Diagnoses (ICD-10 codes) c2 = 0.80, d.f. = 1, P = 0.37
F20 15 (65.2) 12 (52.2)
F21-29 8 (34.8) 11 (47.8)
HoNOS at assessment (SD) 16.26 (6.77) 13.47 (4.06) M–W = 189.00, P = 0.096
All data: mean (SD), or n (%), according to their nature.
d.f., degrees of freedom; HoNOS, Health of the Nation Outcome Scales; ICD, International Classification of Diseases; M–W, Mann–Whitney U test; SD,
standard deviation.
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The typeof treatment (Programma2000 vs. SC) did
not produce a significant effect on HoNOS scores at
the 5-year follow-up after controlling for theHoNOS
scoresat initial assessment: (F(1,43) = 0.55,P = 0.57).
However, at the 5-year follow-up, patients in Pro-
gramma2000 reported a larger absolute decrease,
being 8.3 in Programma2000 (95% CI = 4.3–12.1)
and 4.1 in SC (95%CI = 1.6–6.5) (Mann–Whitney
U = 177.00, z = -1.92, P = 0.054).
Patients with RC  7 constituted 60.9% (n=14) in
Programma2000 and 34.8% in SC (c2 = 2.17, d.f. = 1,
P = 0.14). The NNT, on the basis of RC, was 3.8 (i.e.
4), which is close to a medium effect.
After 5 years of treatment, 14 patients (60.8%) in
Programma2000 were determined to have no or
minimal severe symptoms on the HoNOS; the cor-
responding figure in the SC group was 10 (43.4%)
(c2 = 0.78, d.f. = 1, P = 0.37).
Costs analysis
Average costs per patient over 5 years were quite
similar, being € 39 671 for the index and € 42 810 for
the contrast group (Table 3). The average cost per
day of treatment was € 22.6 and € 23.0, respectively.
In Programma2000, allocation of costs was:
outpatient care = 77.4%, inpatient care = 9.9%,
residential facilities care = 12.7%. The correspond-
ing figures in SC were: 59.1%, 25.6% and 15.3%,
respectively.
Patients in Programma2000 were marginally less
likely to be treated in day hospital (Fisher’s exact
test P = 0.109) and, on average, had been hospital-
ized for shorter periods. Therefore their hospital
costs were far lower than the SC group (€ 3928 vs.
€ 10 969; respectively) (Mann–Whitney U = 207.00,
z = -2.33, P = 0.019 (AUC = 0.609, but 95%CI =
0.444–0.773) (Table 3).
Patients in Programma2000 were also marginally
less likely to have been admitted to semi-
residential facilities (Fisher’s exact test P = 0.165),
so costs for semi-residential facilities care, too,
were also lower in Programma2000 in comparison
to the SC group, though this did not reach statisti-
cal significance (Mann-Whitney U = 198.00, z =
-1.71, P = 0.086).
TABLE 2. Outcome after 5 years of treatment
Programma2000 Standard Care
n = 23 Effect size (95%CI) n = 23 Effect size (95%CI)
HoNOS behavioural problems
Pre-treatment 1.82 (1.80) -0.77 2.17 (1.61) -0.85
Post-treatment 0.65 (1.11)* (-1.37; -0.17) 0.95 (1.18)* (-1.45; -0.25)
HoNOS general impairment
Pre-treatment 1.95 (1.39) -0.73 0.95 (0.92) 0.22
Post-treatment 0.91 (1.41)* (-1.33; -0.13) 1.21 (1.34) (-0.36; 0.80)
HoNOS clinical symptoms
Pre-treatment 5.91 (2.77) -1.15 5.08 (2.72) -0.57
Post-treatment 2.95 (2.28)* (-1.77; -0.52) 3.65 (2.18) (-1.16; 0.02)
HoNOS psychosocial problems
Pre-treatment 6.56 (3.46) -0.88 5.26 (2.43) -0.67
Post-treatment 3.47 (3.48)* (-1.48; -0.27) 3.56 (2.59)* (-1.26; -0.07)
HoNOS total score
Pre-treatment 16.26 (6.77) -1.27 13.47 (4.06) -0.85
Post-treatment 8.00 (5.94)* (-1.91; -0.64) 9.39 (5.29)* (-1.45; -0.25)
% changes in HoNOS from entry to 5-year follow-up
Mean (SD) -37.5% (65.2%) -19.3% (72.2%)
Median (interquartile range) -54.5 (63.3) -22.2 (66.6)
HoNOS cut-offs at 5 years (n, %)
No severe symptoms (= 0) 1 (4.3%) 0 (0%)
Light severe symptoms (1–7)) 13 (56.5%) 10 (45.3%)
Moderately severe symptoms (8–14) 6 (26.1%) 9 (39.1%)
Severe symptoms (15–21) 2 (8.7%) 4 (17.4%)
Very severe symptoms (22) 1 (4.3%) 0 (0%)
HoNOS RC (n, %) 14 (60.9%) 8 (34.8%)
*Wilcoxon signed rank test, post-treatment versus pre-treatment, P < 0.05.
All data: mean (SD), or n (%), according to their nature.
CI, confidence interval; HoNOS, Health of the Nation Outcome Scales; RC, reliable change index; SD, standard deviation.
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In contrast, outpatient treatment was more
intensive in Programma2000 than in SC, which is
reflected in the higher costs for outpatient inter-
ventions: (€ 30 701 vs. € 25 292: AUC = 0.733, 95%
CI = 0.583–0.884).
Cost-effectiveness of early treatment
The average cost per score of reduction on the
HoNOS scale was € 4802 for the Programma2000
group and € 9871 for the SC group. Beingmore cost-
effective, the incremental cost-effectiveness ratio
(ICER) of Programma2000 over SC is € -1204 per
incremental score of reduction, which means that a
net saving of € 1204 per score is achieved if patients
are treated with an EIP instead of a SC programme.
Similarly, the average cost per patient with a RC
is € 65 173 with EI and 115 982 with SC; the ICER is
€ -8468 per patient with RC, which is a significant
net saving.
Costs of treatment over time and
sensitivity analysis
Average costs were higher in the first 2 years of treat-
ment for patients in Programma2000, after which
they decreased (Friedman test’s P = 0.0001, post-
hoc Dunn’s P < 0.05 from assessment to the fourth
and fifth year), whereas they increased smoothly
over time among patients in SC (Friedman test’s
P = 0. 0281, Dunn’s P > 0.05 in all comparisons),
concurrently to a higher chance of hospitalization
(Fig. 1).
As the cost profiles over the 5-year treatment are
different between the two groups, the average per
patient cost, discounted at 3% or 5% annually com-
pounded, would be somewhat lower for the SC
group (because many costs occur in the last years,
contrary to Programma2000), but the cost-
effectiveness ratio would still favour the Pro-
gramma2000 group (€ 4520 vs. € 8646 per reduced
score, if discounted at 3%, and € 4639 vs. € 9127,
if discounted at 5%, with an ICER of € -988 and
€ -1075, respectively).
DISCUSSION
The main finding of this study is that patients with
first-episode psychosis enrolled in an EIP in Milan,
TABLE 3. Cost-analysis of treatment over 5 years, early intervention in psychosis (Programma2000) versus Standard Care
Programma2000
n = 23
Standard Care
n = 23
n (%) Days of use* Mean (SD) n (%) Days of use* Mean (SD)
Outpatient interventions
Total outpatient costs 23 (100) n.a. 30 701 (19 789) 23 (100) n.a. 25 292 (32 910)
Inpatient interventions
Hospital inpatient care 9 (39) 242 3 928 (6 631) 13 (56) 542 9833 (19 794)
Day hospital care 0 (-) 0 0.0 (0.0) 4 (17) 64 1136 (2 341)
Total inpatient costs 3 928 (6 631) 10 969 (20 065)
Residential care
Residential facilities 1 (4) 546 3 072 (14 732) 1 (4) 734 4130 (19.805)
Semi-residential facilities 3 (13) 376 1 970 (9 181) 8 (35) 1121 2419 (7 527)
Total residential care costs 5 042 (17 221) 6549 (20 688)
Total costs of care 23 (100) 39 671 (35 089) 23 (100) 42 810 (72 155)
*Days of use are intended as days of utilization of the specific facility (length of stay), and are expressed as the total amount for all patients across all the
5 years. Days of use are n.a. for outpatient interventions, since costs for these are not calculated by day of use.
Data expressed in Euros at constant year 2006 prices – costs over 5 years, mean per patient (SD).
n.a., not available; SD, standard deviation.
FIGURE 1. Overall costs of treatment over time, from assessment
to 5-year follow-up in early intervention in psychosis (Pro-
gramma2000 vs. Standard Care) – Data expressed in Euros at
2006 constant prices. , Programma 2000 (n = 23); , Standard
Care (n = 23).
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Italy, showed a better improvement at the 5-year
follow-up than those enrolled in SC. The potential
bias of a ‘floor effect’ in the changes of pre- to post-
treatment scores on the HoNOS cannot be disre-
garded, because patients in SC were marginally less
severe at initial assessment than those in the Pro-
gramma2000, and so had less room for improve-
ment at the 5-year follow-up. However, at the 5-year
follow-up a larger number of patients in the SC
group had HoNOS scores in the moderately severe
to very severe range (56.5%) compared with those in
the Programma2000 (39.1%). Thresholds for symp-
toms severity are based on absolute values and do
not depend on relative size with respect to initial
assessment.
As therapists in both settings are likely to follow
the same guidelines for pharmacotherapy, the addi-
tional reported benefits are supposed to come from
the intensive outpatient care programme offered
in Programma2000, based on psychotherapy, psy-
choeducation, social support and competency
training.7,20 SC usually does not provide this type
of treatment,23,25 which is costly and primarily
produces indirect effects on the quality of life and
family burden. The intensive outpatient treatment
in Programma2000 also succeeded in reducing hos-
pital admission rates and use of day hospital,
although statistical differences were at a trend level
only because of the small sample size. These results
are consistent with the aim of deinstitutionalization
and better community care. However, in Italy, there
are large differences among areas concerning the
provision and the quality of care for people with
mental disorders. In particular, the frequency
and intensity of psychosocial interventions – the
major strength in the treatment package of
Programma2000 – was uneven across different
geographical areas.32
Total treatmentcostsweresimilarbetweenthe two
groups over a 5-year treatment period. Outpatient
costs were higher in the Programma2000 than in the
SC group, but they were compensated by lower hos-
pital costs and,marginally, residential care costs.The
Programma2000costswereconcentratedandhigher
in the first 2 years of treatment, decreasing thereaf-
ter,while theSCgroupcosts increasedyearafteryear.
Data after the fifth year of treatment are being col-
lected to assess whether Programma2000 patients
have consolidated their lower level of severity and
continue to have lower costs than the SC group.
A similar trend (higher costs than SC at settle-
ment, but cost savings at follow-up) was observed in
a recent theoretical cost-effectiveness analysis using
data fromOutreach and Support in South London.33
Similarly, another theoretical probabilistic model,
based on data from real studies, found higher costs
at the start of treatment in EIPs than in SC, but lower
costs in the long run at 3 years.34 Finally, results
based on real data from the Lambeth Early Onset
service and compared with SC in the same area
(south London) provide evidence of the cost-
effectiveness of EIPs, with findings similar to the
Programma2000. Costs were higher for outpatient
interventions and lower for hospital-based inter-
ventions in the EI service than in SC, although
overall, differences between the services were not
statistically significant.35 Even the Danish OPUS
study, which found no clear clinical benefits at a
5-year follow-up after 2-year treatment in EI service,
still showed that differences in inpatient services
favoured EI over SC.36
In fact, the main difference between Pro-
gramma2000 and SC is the better allocation of
resources required to achieve improvement: the
ICER of Programma2000 over SC is € -1204 per
incremental score of reduction, a net saving. This
occurs with a wide variability across patients, as a
reflection of the large variation in the clinical effec-
tiveness of treatment at patient level (a finding
already reported in Italy).37
Average yearly costs per patient were strictly com-
parablewith past Italian studies, taking into account
inflation: € 7934 in Programma2000 and € 8562 in
SC; € 7500 in Tarricone et al.38 € 7025 in Garattini
et al.37 Indirect costs attributable to schizophrenia
are known to be consistently higher than direct care
costs,38 but this was not the study purpose.
Limitations and strengths
The small sample size is the main limitation of
this study, which precludes multivariate analyses.
Nevertheless socio-demographic variables did not
differ between the two compared groups, so it is
unlikely that an interaction effect has resulted.
Another issue are the significant differences in the
provision of psychiatric care across Italy,32 which
limits the possibility of generalizing the results of
this study.
In this research, clinicians assigned the scores on
the HoNOS, which may have affected overall rating,
however any bias would have occurred in both
settings, so should not be relevant with respect to
the final results. A greater limitation is the lack of
detailed information at assessment for patients in
SC: standard assessments are not conducted as part
of public psychiatric services in Italy.We had to rely
entirely on the HoNOS, which was not designed to
cover all the aspects of outcomes, but principally
reflect the staff’s view of the situation.39 However, it
C. Angelo et al.
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has cross-cultural validity and the ability to predict-
ing awide range of outcomes, including admissions,
bed days and psychiatric contacts,40,41 relevant to
the aims of this study. Furthermore, we have data on
a sample of patients who received 5 years of treat-
ment, with continuity of care and no dropout.
Therefore, we can be confident that results are not
affected by bias due to selective assessment.
CONCLUSIONS
This is the first study on costs of EIP services ema-
nating from a non-Anglo-Saxon or Scandinavian
country: its is entirely based on real costs data, cal-
culated patient by patient, and cover a total direct
health care period of 5 years. The study results are
consistent with the assumption that the provision of
phase-specific, tailored interventions in psychosis
might relieve the burden of illness for patients, their
families and, potentially, society at large, because of
better use of resources. Therefore, a reallocation of
funds that could allow for the increased application
of intensive early intervention treatment in psycho-
sismight be opportune, especially because themost
expensive specialized outpatient care programmes
can ultimately save on costs by reducing the use of
hospital and residential facilities, thus producing
net cost savings in the long term.
ACKNOWLEDGEMENTS
The authors acknowledge the invaluable support
and help of Dr Antonio Lora in the search and
collection of control data in Standard Care.
Programma2000 is entirely financed by a grant from
the Lombardy Regional Health Authority (Italy). The
Lombardy Regional Health Authority had no further
role in study design; in the collection, analysis and
interpretation of data; in the writing of the report;
and in the decision to submit the paper for publica-
tion. No other forms of financial support were
received for this study.
REFERENCES
1. Lauber C, Keller C, Eichenberger A et al. Family burden
during exacerbation of schizophrenia: quantification and
determinants of additional costs. Int J Soc Psychiatry 2005;
51: 259–64.
2. Murray CJL, Lopez AD. The Global Burden of Disease: A
Comprehensive Assessment of Mortality and Disability from
Diseases, Injuries, and Risk Factors in 1990 and Projected to
2020. Cambridge: Harvard University Press, 1996.
3. Saha S, Chant D, McGrath J. A systematic review of
mortality in schizophrenia. Is the differential mortality gap
worsening over time? Arch Gen Psychiatry 2007; 64: 1123–
31.
4. Goeree R, Farahati F, Burke N et al. The economic burden of
schizophrenia in Canada in 2004. Curr Med Res Opin 2005;
21: 2017–28.
5. Knapp M, Mangalore R, Simon J. The global costs of schizo-
phrenia. Schizophr Bull 2004; 30: 279–93.
6. Mangalore R, Knapp M. Cost of schizophrenia in England. J
Ment Health Policy Econ 2007; 10: 23–41.
7. Edwards J, McGorry PD. Implementing Early Intervention in
Psychosis. A Guide to Establishing Early Psychosis Services.
London: Dunitz, 2002.
8. Larsen TK, Friis S, Haahr U et al. Early detection and interven-
tion in first-episode schizophrenia: a critical review. Acta
Psychiatr Scand 2001; 103: 323–34.
9. Killackey E, Yung AR. Effectiveness of early intervention in
psychosis. Curr Opin Psychiatry 2007; 20: 121–5.
10. Marshall M, Lewis S, Lockwood A et al. Association between
duration of untreated psychosis and in cohorts of first-
episode outcome patients – a systematic review. Arch Gen
Psychiatry 2005; 62: 975–83.
11. Killackey EJ, Jackson HJ, Gleeson J et al. Exciting career
opportunity beckons! Early intervention and vocational reha-
bilitation in first-episode psychosis: employing cautious opti-
mism. Aust N Z J Psychiatry 2006; 40: 951–62.
12. Major BS, Hinton MF, Flint A et al. Evidence of the effective-
ness of a specialist vocational intervention following first
episode psychosis: a naturalistic prospective cohort study.
Soc Psychiatry Psychiatr Epidemiol 2010; 45: 1–8.
13. Gleeson JF, Cotton SM, Alvarez-Jimenez M et al. A random-
ized controlled trial of relapse prevention therapy for first-
episode psychosis patients. J Clin Psychiatry 2009; 70: 477–
86.
14. Perkins DO, Gu H, Boteva K et al. Relationship between dura-
tion of untreated psychosis and outcome in first-episode
schizophrenia: a critical review and meta-analysis. Am J Psy-
chiatry 2005; 162: 1785–804.
15. McGorry PD, Edwards J, Mihalopoulos C et al. EPPIC: an
evolving system of early detection and optimal management.
Schizophr Bull 1996; 22: 305–26.
16. Mihalopoulos C, McGorry PD, Carter RC. Is phase-specific,
community-oriented treatment of early psychosis an eco-
nomically viable method of improving outcome? Acta Psy-
chiatr Scand 1999; 100: 47–55.
17. Mihalopoulos C, Harris M, Henry L, Harrigan S, McGorry P. Is
early intervention in psychosis cost-effective over the long-
term? Schizophr Bull 2009; 35: 909–18.
18. Cullberg J, Mattsson M, Levander S et al. Treatment costs and
clinical outcome for first episode schizophrenia patients: a
3-year follow-up of the Swedish ‘Parachute Project’ and two
comparison groups. Acta Psychiatr Scand 2006; 114: 274–
81.
19. Harrison G, Hopper K, Craig T et al. Recovery from psychotic
illness: a 15- and 25-year international follow-up. Br J Psy-
chiatry 2001; 178: 506–17.
20. Cocchi A, Meneghelli A, Preti A. ‘Programma 2000’: celebrat-
ing ten years of activity of an Italian pilot program on early
intervention in psychosis. Aust N Z J Psychiatry 2008; 42:
1003–12.
21. Fusar-Poli P, Meneghelli A, Valmaggia L et al. Duration of
untreated prodromal symptoms and 12-month functional
outcome of individuals at risk of psychosis. Br J Psychiatry
2009; 194: 181–2.
22. Preti A, Rucci P, Gigantesco A et al. Patterns of care in
patients discharged from acute psychiatric inpatient facili-
ties: a national survey in Italy. Soc Psychiatry Psychiatr
Epidemiol 2009; 44: 767–76.
Costs of early intervention in psychosis
210 © 2011 Blackwell Publishing Asia Pty Ltd
23. Gigantesco A, Miglio R, Santone G et al. The process of care
in general hospital psychiatric units: a national survey in Italy.
Aust N Z J Psychiatry 2007; 41: 509–18.
24. Lora A, Cosentino U, Gandini A et al. Which community care
for patients with schizophrenic disorders? Packages of care
provided by Departments of Mental Health in Lombardy
(Italy). Epidemiol Psichiatria Soc 2007; 16: 330–8.
25. Ruggeri M, Bacigalupi M, Casacchia M et al. Care across all
phases of schizophrenia and initiation of treatment: discrep-
ancy between routine practice and evidence. The SIEP-
DIRECT’S Project. Epidemiol Psichiatria Soc 2008; 17: 305–
18. (In Italian)
26. World Health Organization. Tenth Revision of the Interna-
tional Classification of Diseases and Related Health Problems
(ICD-10). Geneve, Switzerland: World Health Organization
Press, 1992.
27. Wing JK, Beevor AS, Curtis RH et al. Health of the Nation
Outcome Scales (HoNOS). Research and development. Br J
Psychiatry 1998; 172: 11–18.
28. Parabiaghi A, Barbato A, D’Avanzo B et al. Assessing reliable
and clinically significant change on Health of the Nation
Outcome Scales: method for displaying longitudinal data.
Aust N Z J Psychiatry 2005; 39: 719–25.
29. Kraemer HC, Kupfer DJ. Size of treatment effects and their
importance to clinical research and practice. Biol Psychiatry
2006; 59: 990–6.
30. Hakstian AR, Whalen TE. A k-sample significance test for
independent alpha coefficients. Psychometrika 1976; 41:
219–23.
31. Arrighi E, di Maio A, Mapelli V. Il costo dei pazienti. Epide-
miol Psichiatr Soc 2002; 11 (Suppl. 4): 53–65. (In Italian)
32. de Girolamo G, Bassi M, Neri G et al. The current state of
mental health care in Italy: problems, perspectives, and
lessons to learn. Eur Arch Psychiatry Clin Neurosci 2007; 257:
83–91.
33. Valmaggia LR, McCrone P, Knapp M et al. Economic impact
of early intervention in people at high risk of psychosis.
Psychol Med 2009; 39: 1617–26.
34. McCrone P, Martin Knapp M, Dhanasiri S. Economic impact
of services for first-episode psychosis: a decision model
approach. Early Interv Psychiatry 2009; 3: 266–73.
35. McCrone P, Craig TKJ, Power P, Garety PA. Cost-effectiveness
of an early intervention service for people with psychosis. Br
J Psychiatry 2010; 196: 377–82.
36. Bertelsen M, Jeppesen P, Petersen L et al. Five-year follow-up
of a randomized multicenter trial of intensive early interven-
tion vs standard treatment for patients with a first episode of
psychotic illness. Arch Gen Psychiatry 2008; 65: 762–71.
37. Garattini L, Barbui C, Clemente C et al. Direct costs of schizo-
phrenia and related disorders in Italian community mental
health services: a multicenter, prospective 1-year followup
study. Schizophr Bull 2004; 30: 295–302.
38. Tarricone R, Gerzeli S, Montanelli R et al. Direct and indirect
costs of schizophrenia in community psychiatric services in
Italy: the GISIES study. Health Policy 2000; 51: 1–18.
39. Orrell M, Yard P, Handysides J, Schapira R. Validity and reli-
ability of the Health of the Nation Outcome Scales in psychi-
atric patients in the community. Br J Psychiatry 1999; 174:
409–12.
40. Kisely S, Campbell LA, Cartwright J, Cox M, Campbell J. Do
the health of the nation outcome scales measure outcome?
Can J Psychiatry 2010; 55: 431–9.
41. Pirkis JE, Burgess PM, Kirk PK, Dodson S, Coombs TJ, Will-
iamson MK. A review of the psychometric properties of the
Health of the Nation Outcome Scales (HoNOS) family of
measures. Health Qual Life Outcomes 2005; 3: 76.
C. Angelo et al.
© 2011 Blackwell Publishing Asia Pty Ltd 211
